tarveda.com
Tarveda Therapeutics | Board of Directors
http://www.tarveda.com/bod.html
Benefits of Miniaturized Biologic Drug Conjugates. President, Chief Executive Officer and Interim Chairman. Dennis Ausiello, MD. Jackson Professor of Clinical Medicine, Harvard Medical School and Massachusetts General Hospital. M James Barrett, PhD. General Partner, NEA. Omid Farokhzad, MD. Blend (Now Tarveda) Founder and Associate Professor, Harvard Medical School. Edwin Kania, Jr. Managing Partner, Flagship Ventures. Guido Magni, MD, PhD. Versant Venture Management, LLC. Nilesh Kumar, PhD. Nilesh recei...
tarveda.com
Tarveda Therapeutics | Press Releases
http://www.tarveda.com/press.html
Benefits of Miniaturized Biologic Drug Conjugates. March 1, 2017. Tarveda Announces Presentation and Panel Participation at Upcoming Conferences. February 9, 2017. Tarveda to Present at the BIO CEO and Investor Conference February 14. February 2, 2017. Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates. January 5, 2017. Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2017. January 5, 2017. January 4, 2017. April 21, 2015.
tarveda.com
Tarveda Therapeutics | PEN-221
http://www.tarveda.com/PEN-221.html
Benefits of Miniaturized Biologic Drug Conjugates. Website by The Yates Network.
tarveda.com
Tarveda Therapeutics | Scientific Advisors
http://www.tarveda.com/advisors.html
Benefits of Miniaturized Biologic Drug Conjugates. Tarveda has assembled a world-class team of scientific advisors that includes recognized experts in the fields of cancer metabolism, oncology, drug discovery, medicinal chemistry, nanomedicine, nanoparticle engineering, and drug delivery. These advisors work closely with Tarveda scientists to identify research directions as well as optimal combinations for Tarveda’s integrative medicines. Neil H. Bander, MD. Kapil Dhingra, MD. Sangyong Jon, PhD. Associat...
tarveda.com
Tarveda Therapeutics | Careers
http://www.tarveda.com/careers.html
Benefits of Miniaturized Biologic Drug Conjugates. Tarveda Therapeutics is building a team to discover and develop transformational medicines that truly impact the lives of cancer patients. Working toward a cure is our goal. Significantly raising the standard of care is our starting point. We are applying our novel technologies to make advances beyond today’s cancer treatments to benefit patients and their families. Do you want to add your outstanding skills and expertise to the vibrant team at Tarveda?
tarveda.com
Tarveda Therapeutics | PENTARIN™ Platform
http://www.tarveda.com/pentarin.html
Benefits of Miniaturized Biologic Drug Conjugates. Benefits of Miniaturized Biologic Drug Conjugates. A New Paradigm for Miniaturized Drug Conjugates. Pentarins: Designed to Maintain Miniature Size and Address Treatment Challenges in Solid Tumors. The Pentarin platform enables the Tarveda team to design the properties of each Pentarin for optimized efficacy in the targeting of solid tumors. Our Pentarins are engineered to effectively penetrate into solid tumors to drive efficacy, through the inherent...
tarveda.com
Tarveda Therapeutics | How and Pentarins™ Work
http://www.tarveda.com/howpentarins.html
Benefits of Miniaturized Biologic Drug Conjugates. Tarveda’s proprietary Pentarins are miniaturized drug conjugates,. A class of cancer therapeutics uniquely designed to target, penetrate and treat solid tumors. Pentarins are designed to maintain their miniature size and overcome biological barriers in solid tumors through two distinct capabilities as highlighted in the name “PENTARIN”:. The PEN in Pentarin represents the penetration into solid tumors. Benefits of Miniaturized Biologic Drug Conjugates.
promedior.com
Promedior Publications
http://www.promedior.com/news/publications.html
Pentraxin-2 Mechanism of Action. Potential of Pentraxin-2 Therapeutics. Van den Blink B, et al. (2016) Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. J Eur Respir J. 2016 Feb 11. [Epub ahead of print]. Verna EC, et al. (2015) Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. Epub ahead of print June 29. Murray LA, et al....
promedior.com
Promedior Pipeline
http://www.promedior.com/pipeline/pipeline.html
Pentraxin-2 Mechanism of Action. Potential of Pentraxin-2 Therapeutics. Promedior is advancing its product candidates through clinical studies to demonstrate its ability to address the unmet needs of patients in a number of serious fibrotic diseases. The company is currently focused on rare fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and myelofibrosis, and we are also interested in retinal fibrovascular diseases such as age-related macular degeneration (AMD). PRM-151 has demonstrated e...
promedior.com
Promedior Careers
http://www.promedior.com/careers/positions.html
Pentraxin-2 Mechanism of Action. Potential of Pentraxin-2 Therapeutics. Following are current openings that will be located in the Greater Boston/Cambridge area:. Interested candidates should forward email their resume to jobs@promedior.com. Thank you for considering Promedior. At Promedior, we are focused on developing novel therapeutics to address the unmet needs of patients with fibrosis.